The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD

Posttraumatic Stress Disorder (PTSD) is a chronic and debilitating psychiatric conditioncharacterized by intrusive memories, avoidance behaviors, hyperarousal, and emotionalnumbing. It is estimated that it affects 5.3% of the Israeli general population, thoughfollowing the October 7, 2023 terror attacks, probable PTSD nearly doubled, from 16.2% to29.8%, highlighting the urgent national need for effective and scalable PTSDinterventions.Given its high prevalence and physical and mental consequences, adequate treatment isneeded. Current first‐line therapies (TF‐CBT and EMDR) are effective but aretime‐intensive, require specialized clinicians, and are not suitable for all patients.Pharmacological interventions, particularly SSRIs yield partial response rates ( 60%) andoften cause adherence‐limiting side effects (e.g., major changes in body weight or lossof sexual drive). These limitations underscore the need for novel, tolerable, andmechanistically targeted therapies.Arising evidence suggests a correlation between sensory dysfunction, impaired attention,and PTSD symptoms. The importance of combined treatment specifically targeting thesedifficulties has been suggested by us. Recent evidence suggests that PTSD involvesdysregulation in both noradrenergic and dopaminergic systems, which play critical rolesin attention, arousal, and emotional processing. Reboxetine, a norepinephrine reuptakeinhibitor (NRI), and methylphenidate, a dopamine‐enhancing psychostimulant, arehypothesized to have synergistic effects on PTSD‐related cognitive and emotionaldeficits. Our lab's prior results suggest that this combination is safe, well‐tolerated,and effective in reducing both clinician‐rated PTSD symptoms, and neurophysiologicaldysregulations related to sensory gating and attention regulation, sensory processing,participation and quality of life.Animal‐assisted therapies, and DAT in particular, are increasingly recognized for theirpotential to reduce PTSD symptoms and improve emotional regulation. DAT programs for USveterans diagnosed with PTSD were found to be a helpful complementary or alternativetreatment option for the veterans, demonstrating signs of meaningful improvements inmental and social health, lower PTSD symptoms severity and higher psychosocialfunctioning in veterans owning a psychiatric service dog, and positive correlationbetween Animal‐assisted interventions (AAI) and a reduction of posttraumaticsymptomatology. DAT programs have also been shown to foster resilience among veterans andtheir families. A meta‐review found that DAT was as effective as traditionalpsychotherapy in symptom reduction. Our lab conducted a controlled study involvingadolescents exposed to interpersonal trauma, showing significant improvement in PTSDsymptoms, depression, and attentional regulation after a year‐long dog training program(also on the dogs' attention and anxiety‐like behavior).Despite growing support for DAT and emerging evidence comparing DAT to psychotherapeuticinterventions for PTSD symptomatology, no studies to date have directly comparedpharmacological vs. animal‐assisted therapy in PTSD. Moreover, there is a lack ofobjective, physiology‐based tools to monitor treatment efficacy and guide individualizedcare. This study aims to bridge both gaps, combining a novel pharmacological strategywith neurophysiological diagnostics in a rigorously controlled, head‐to‐head RCT.Therefore, a four‐arm randomized controlled trial (RCT) involving 160 adults diagnosedwith PTSD, allocated to one of the following groups: 1. Combined pharmacologicaltreatment (reboxetine + methylphenidate) 2. Pharmacological placebo control 3.Dog‐assisted therapy (DAT) 4. Active control: Occupational therapy (OT) Thepharmacological arm is double‐blinded and placebo‐controlled, while the DAT/OT arms areopen‐label, with participant preference and suitability guiding allocation. The studyincludes repeated measurements at multiple time points, combining subjective andobjective outcomes.